Senda Biosciences

Kintai Therapeutics, Inc. is focused on developing small-molecule therapeutics that target the microbiome, gut immune cells, and the enteric nervous system. Founded in 2016 and based in Cambridge, Massachusetts, the company leverages its Precision Enteric Medicines™ (PEM™) discovery platform, which utilizes AI-based algorithms to identify and create orally available small molecules aimed at addressing various health conditions. Kintai's drug development efforts encompass a range of therapeutic areas, including autoimmune disorders, cancer, chronic kidney disease, nonalcoholic steatohepatitis, and neurological conditions like multiple sclerosis, as well as treatments for hyperlipidemia and obesity. The company's innovative approach aims to harness the body's signaling networks to restore health and combat disease effectively.

Omega Therapeutics is a development-stage biotechnology company based in Cambridge, Massachusetts, focused on developing genomic medicines aimed at curing diseases. The company utilizes its proprietary epigenomic programming platform to create a new class of programmable epigenetic medicines, referred to as Omega Epigenomic Controllers. These controllers are designed to selectively modulate genomic activity, enabling precise tuning of the human genome to treat various medical conditions. Founded in 2016 and rebranded from VL42, Inc. in 2017, Omega Therapeutics is dedicated to transforming human medicine by harnessing the innate potential of the genome for therapeutic benefits.